Pemetrexed (Alimta)
Comparison of First-Line Chemotherapeutics and Validation of the EORTC Prognostic Index in Malignant Pleural Mesothelioma: Retrospective Single-Centre Experience
Journal of the College of Physicians and Surgeons 2024 August [Link] Yasin Sezgin, Ogur Karhan, Serdar Ileri, Senar Ebinc, Sezai Tunc, Zuhat Urakci Abstract Objective: To evaluate the efficiency of pemetrexed cisplatin in comparison with gemcitabine cisplatin and to validate the EORTC (European Organisation for Research and Treatment of Cancer) prognostic score in combination chemotherapy…
Read MoreChemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment
Scientific Reports 2024 August 6 [Link] Darya Karatkevich, Tereza Losmanova, Philipp Zens, Haibin Deng, Christelle Dubey, Tuo Zhang, Corsin Casty, Yanyun Gao, Christina Neppl, Sabina Berezowska, Wenxiang Wang, Ren-Wang Peng, Ralph Alexander Schmid, Patrick Dorn, Thomas Michael Marti Abstract The combination of cisplatin and pemetrexed remains the gold standard chemotherapy for malignant pleural mesothelioma (MPM),…
Read MoreContemporary management of mesothelioma
Breathe 2024 July 16 [Link] Mark D J Neilly, Jennifer Pearson, Akari Win Thu, Carolyn MacRae, Kevin G Blyth Abstract Pleural mesothelioma (PM) is an aggressive asbestos-associated thoracic malignancy with a median survival of 12-18 months. Due to continued asbestos use in many nations, global incidence is rising. Causes due to non-occupational, environmental exposure are…
Read MoreIntegration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study
PloS One 2024 July 15 [Link] Jolien Van den Bossche, Maxime De Laere, Koen Deschepper, Paul Germonpré, Yvan Valcke, Jan Lamont, Barbara Stein, Kirsten Van Camp, Charlotte Germonpré, Griet Nijs, Ella Roelant, Sébastien Anguille, Eva Lion, Zwi Berneman Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with a very poor prognosis. Recently, immune checkpoint…
Read MoreReal-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial
Lung Cancer 2024 June 29 [Link] Olivier Bylicki, Florian Guisier, Arnaud Scherpereel, Catherine Daniel, Aurélie Swalduz, Emmanuel Grolleau, Marie Bernardi, Stephane Hominal, Jean Briac Prevost, Guillaume Pamart, Marie Héléne Marques, Nicolas Cloarec, Simon Deshayes, Judith Raimbourg, Rémi Veillon, Youssef Oulkhouir, Clarisse Audigier Valette, Fabien Subtil, Christos Chouaïd, Laurent Greillier Abstract Background: First-line standard-of-care for unresectable,…
Read MoreCrosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells
Cell Death and Disease 2023 November 8 [Link] Yakinthi Chrisochoidou, Rajat Roy, Pooyeh Farahmand, Guadalupe Gonzalez, Jennifer Doig, Lukas Krasny, Ella F Rimmer, Anne E Willis, Marion MacFarlane, Paul H Huang, Neil O Carragher, Alison F Munro, Daniel J Murphy, Kirill Veselkov, Michael J Seckl, Miriam F Moffatt, William O C Cookson, Olivier E Pardo…
Read MoreInduction of metallothionein expression by supplementation of zinc induces resistance against platinum-based treatment in malignant pleural mesothelioma
Translational Cancer Research 2023 August 31 [Link] Martine Wyrich, Henning Ohlig, Michael Wessolly, Elena Mairinger, Julia Steinborn, Luka Brcic, Balazs Hegedus, Thomas Hager, Kristina Greimelmaier, Jeremias Wohlschlaeger, Fabian D Mairinger, Sabrina Borchert Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor with a dismal prognosis. Currently, multimodality treatment including chemotherapy with cisplatin or carboplatin…
Read MoreCAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma
Cell Death Discovery 2023 July 21 [Link] Sivasundaram Karnan, Akinobu Ota, Hideki Murakami, Md Lutfur Rahman, Md Wahiduzzaman, Muhammad Nazmul Hasan, Lam Quang Vu, Ichiro Hanamura, Akihito Inoko, Miho Riku, Hideaki Ito, Yoshifumi Kaneko, Toshinori Hyodo, Hiroyuki Konishi, Shinobu Tsuzuki, Yoshitaka Hosokawa Abstract Malignant mesothelioma (MMe) is a rare but aggressive malignancy. Although the molecular…
Read MoreSETDB1 tumour suppressor roles in near-haploid mesothelioma involve TP53
British Journal of Cancer 2023 June 27 [Link] Mengting Xu, Yuqing Tu, Wenhui Bi, Meijun Z Lundberg, Isabella Klooster, Jonathan A Fletcher, Wen-Bin Ou Abstract Background: Mutational inactivation of the SETDB1 histone methyltransferase is found in a subset of mesothelioma, particularly in cases with near-haploidy and TP53 mutations. However, the tumourigenic consequences of SETDB1 inactivation…
Read MoreIndolyl-chalcone derivatives trigger apoptosis in cisplatin-resistant mesothelioma cells through aberrant tubulin polymerization and deregulation of microtubule-associated proteins
Frontiers in Oncology 2023 May 25 [Link] Sophia Steinlein, Frank Essmann, Amanda Franceschini Ghilardi, Heike Horn, Julia Schüler, Angelika Hausser, Lijun Sun, German Ott, Claudia Kalla Abstract Introduction: Malignant pleural mesothelioma (MPM) is a neoplasm with dismal prognosis and notorious resistance to the standard therapeutics cisplatin and pemetrexed. Chalcone derivatives are efficacious anti-cancer agents with…
Read More